Products for Research Use Only
RegisterLogin

Navlimetostat

CAT: 0804-HY-139611-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-139611-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Navlimetostat is a potent, orally active, selective PRMT5-MTA complex inhibitor, with IC50 of 3.6 and 20.5 nM for PRMT5-MTA and PRMT5. Navlimetostat binds to the PRMT5-MTA complex, with KD value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study[1][2].
CAS Number
2630904-45-7
Product Name Alternative
MRTX-1719; BMS-986504
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Histone Methyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mrtx-1719.html
Purity
99.40
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
FC1=C(C=C(C(C#N)=[C@]1[C@]2=C(C3=CC=C4C(C(CN)=NNC4=O)=C3)C=NN2C)OC5CC5)Cl
Molecular Formula
C23H18ClFN6O2
Molecular Weight
464.88
Precautions
H302, H315, H319
References & Citations
[1]Lars D Engstrom, et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer. Cancer Discov. 2023 Aug 8; CD-23-0669.|[2]Christopher R Smith, et al. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers. J Med Chem. 2022 Feb 10;65 (3) :1749-1766.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
PRMT5

Alternative Products

CatalogName
A24354-5Navlimetostat (MRTX-1719) 5mg
A24354-10Navlimetostat (MRTX-1719) 10mg
A24354-1Navlimetostat (MRTX-1719) 1mg
A24354-2Navlimetostat (MRTX-1719) 2mg

Popular Products